SCHEMBL2907610

SCHEMBL2907610

Nc1nc2c(=O)c3c(O)cccc3oc2cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TBK1 Q9UHD2 12/20 0.48
▸ IKBKE Q14164 7/20 0.48
▸ MAOA P21397 4/20 0.44
▸ IDO1 P14902 1/20 0.43
▸ MAOB P27338 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ EGFR P00533 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ ABCC4 O15439 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11367466 0.83 RAB9A (0.49) TBK1MAOAMAOBKDM4ETP53
SCHEMBL2901859 0.82 TBK1 (0.58) TBK1IKBKEMAOAMAOBKDM4E
SCHEMBL11376915 0.75 MAOA (0.40) MAOAKDM4EMEN1USP2LMNA
SCHEMBL2904833 0.73 KDM4E (0.56) TBK1IKBKEMAOBKDM4EMEN1
SCHEMBL2907889 0.73 TTR (0.54) TBK1IKBKEKDM4EMEN1KMT2A
SCHEMBL2907061 0.72 TTR (0.53) TBK1IKBKEKDM4EMEN1KMT2A
SCHEMBL2907068 0.72 TTR (0.53) TBK1IKBKEKDM4EMEN1KMT2A
SCHEMBL11356167 0.72 TBK1 (0.52) TBK1MAOAMAOBKDM4EMEN1
SCHEMBL2910718 0.71 KDM4E (0.55) TBK1IKBKEMAOAKDM4ETP53
SCHEMBL2907432 0.71 TBK1 (0.56) TBK1IKBKEKDM4ENPC1ABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4143042-A ANTIALLERGENS, BRONCHODILATOR AGENTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1979-03-06 — — US claimed
EP-1968981-B1 AZAXANTHONES AND USE THEREOF FOR TREATING TUMORS SUPRATEK PHARMA INC (CA) 2010-08-18 — — EP disclosed
US-7772255-B2 Method of treating tumors with azaxanthones SUPRATEK PHARMA, INC. (CA) 2010-08-10 — — US disclosed
US-20090042923-A1 Method of Treating Tumors with Azaxanthones SEMOV ALEXANDRE 2009-02-12 — — US disclosed
US-20070135473-A1 Method of treating tumors with azaxanthones SUPRATEK PHARMA, INC. 2007-06-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135473-A1 Method of treating tumors with azaxanthones S100A4, S100B, S100P TBK1 2135/4885IKBKE 1437/4885MAOA 3371/4885
US-20090042923-A1 Method of Treating Tumors with Azaxanthones S100A4, S100P, S100B TBK1 2247/4885IKBKE 1422/4885MAOA 2905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback